Blood and fluid testing for cancer biomarkers, from early detection to residual disease monitoring.
Consented intake · your records travel with you · nothing moves without your sign-off
Freenome provides liquid biopsy testing that gathers and analyzes blood and other bodily fluids for biomarkers including DNA, RNA, and proteins. The testing spans early detection through minimum residual disease monitoring. For patients, it offers biomarker information that can guide treatment choices and track how the disease is progressing over time.
Prefer the source? Freenome's own site has more.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how Freenome handles billing.
We don't have confirmed insurance details for Freenome yet. Start a coverage check with your plan, or contact the provider directly.
Answers grounded in Freenome's details here. Educational only; your oncologist directs treatment.
Powered by Navis on opencancer.ai
Other providers in similar categories.
Gather distinctive biomarkers that can guide treatment and monitor disease progression
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Finds clinical trials you actually qualify for — matched to your tumor's biomarkers and treatment history, not a generic keyword search.
This page is general information. Upload your records for analysis specific to YOUR diagnosis.